Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TNFRSF10C Antibodies:
anti-Mouse (Murine) TNFRSF10C Antibodies:
anti-Rat (Rattus) TNFRSF10C Antibodies:
Go to our pre-filtered search.
Human Monoclonal TNFRSF10C Primary Antibody for CyTOF, FACS - ABIN4899000
Barbarotto, Corallini, Rimondi, Fadda, Mischiati, Grill, Vaccarezza, Celeghini: Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. in Journal of cellular biochemistry 2008
Show all 12 Pubmed References
Human Monoclonal TNFRSF10C Primary Antibody for FACS - ABIN4895308
Gojo, Tan, Fang, Sadowska, Lapidus, Baer, Carrier, Beumer, Anyang, Srivastava, Espinoza-Delgado, Ross: Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. in Clinical cancer research : an official journal of the American Association for Cancer Research 2013
Show all 10 Pubmed References
Human Monoclonal TNFRSF10C Primary Antibody for ICC, FACS - ABIN1169230
Wachter, Sprick, Hausmann, Kerstan, McPherson, Stassi, Bröcker, Walczak, Leverkus: cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. in The Journal of biological chemistry 2004
Show all 4 Pubmed References
Human Polyclonal TNFRSF10C Primary Antibody for ELISA, ICC - ABIN4361811
Kawakubo, Okamoto, Iwata, Shin, Okamoto, Yasukochi, Nakayama, Kadowaki, Tsukuba, Yamamoto: Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface. in Cancer research 2007
Show all 4 Pubmed References
Human Monoclonal TNFRSF10C Primary Antibody for FACS - ABIN1383917
Baritaki, Katsman, Chatterjee, Yeung, Spandidos, Bonavida: Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. in Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 2 Pubmed References
Human Monoclonal TNFRSF10C Primary Antibody for WB - ABIN1383734
Vermot-Desroches, Sergent, Bonnin, Wijdenes: Characterization of monoclonal antibodies directed against trail or trail receptors. in Cellular immunology 2005
Human Monoclonal TNFRSF10C Primary Antibody for FACS - ABIN1383918
Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. in Molecular and cellular biology 2006
High levels of TRAIL-R3 and CCR-2 expression in tumor epithelial cells identified patients with early breast cancer with poor outcomes.
Results identified epigenetic inactivation of TNFRSF10C and TNFRSF10D (show TNFRSF10D Antibodies) in majority of cervical cancer cases.
DcR1 levels in serum sample which were significantly lower in AMD (show AMD1 Antibodies) patients.
DcR1 upregulation mediates temozolomide resistance.
The membrane expression of the TRAIL receptors DR4 (show HLADRB4 Antibodies), DR5 (show TNFRSF10B Antibodies), DcR1 and DcR2 (show CCR6 Antibodies) is greater in normal endometrium than endometrioid adenocarcinoma (EAC (show CYLD Antibodies)). The level of the receptors in EAC (show CYLD Antibodies) is not dependent on grading and staging and does not predict survival.
the results presented here claim for a relevant impact of aberrant methylation of decoy receptors in melanoma and allow to understand how the silencing of DcR1 and DcR2 (show CCR6 Antibodies) is related to melanomagenesis.
GATA4 (show GATA4 Antibodies) and DcR1 promoter hypermethylation is tumor specific event in glioblastoma but they promoter methylation cannot be considered as a prognostic marker of glioblastoma survival.
Primary EOC is associated to a lower TRAIL-R3 expression.
Data show that about 20% of AML (show RUNX1 Antibodies) patients highly expressed decoy receptor TRAIL-R3, which was strongly correlated to a shortened overall survival.
Decoy receptors DcR1 and DcR2 (show CCR6 Antibodies) on CD8 (show CD8A Antibodies)+ T cells, but not on CD4 (show CD4 Antibodies)-positive T cells, are positively correlated with patients' DAS (show ube3a Antibodies) scores.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.
TNF-related apoptosis-inducing ligand receptor 3
, antagonist decoy receptor for TRAIL/Apo-2L
, cytotoxic TRAIL receptor-3
, decoy TRAIL receptor without death domain
, decoy receptor 1
, lymphocyte inhibitor of TRAIL
, tumor necrosis factor receptor superfamily member 10C
, tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain